Eli Lilly (LLY) shares are approaching the $900 mark, fueling speculation about a potential stock split. While a split would not alter the company’s fundamentals, it could enhance liquidity and attract a broader investor base, signaling management’s confidence in sustained growth. Eli Lilly’s strong performance in the obesity and metabolic health sectors, particularly through its incretin-based drugs Mounjaro and Zepbound, underpins this optimism.
In fiscal 2025, Eli Lilly reported a 45% revenue increase to approximately $65.2 billion, with earnings per share rising 86% to $24.2. The company anticipates revenue for fiscal 2026 to reach between $80 billion and $83 billion, despite expected pricing pressures. Notably, GLP-1 drug penetration remains low among eligible patients, indicating substantial growth potential. Additionally, Eli Lilly’s commitment of over $55 billion to manufacturing expansion and the advancement of 36 late-stage programs further solidifies its growth trajectory.
Given these robust fundamentals and market positioning, Eli Lilly appears well-prepared for a potential stock split in 2026, making it a stock to watch for investors seeking growth opportunities.
Source: fool.com